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Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) typically leads to effacement of the nodal architecture by an
infiltrate of malignant cells. Rarely (<1%), DLBCL can present with an interfollicular pattern (DLBCL-IF) preserving the
lymphoid follicles. It has been postulated that DLBCL-IF is derived from marginal zone B cells and may represent a
large-cell transformation of marginal zone lymphoma (MZL), however no direct evidence has been provided to
date. Here we describe a rare case of a diagnostically challenging DLBCL-IF involving a lymph node in a patient
with a prior history of lymphadenopathy for several years and MZL involving skin.
Case presentation: A 53-year old man presented to our Dermatology Clinic due to a 1-year history of generalized
itching, fatigue of 2–3 month’s duration, nausea and mid back rash that was biopsied. PET (positron emission
tomography)/CT (computed tomography) was performed and revealed inguinal, pelvic, retroperitoneal, axillary, and
cervical lymphadenopathy. The patient was referred to surgery for excisional biopsy of a right inguinal lymph node.
Diagnostic H&E stained slides and ancillary studies were reviewed for the lymph node and skin specimens. B-cell
clonality by PCR and sequencing studies were performed on both specimens.
We demonstrate that this patient’s MZL and DLBCL-IF are clonally related, strongly suggesting that transformation
of MZL to DLBCL had occurred. Furthermore, we identified a novel deletion of the long arm of chromosome 20
(del(20q12)) and a missense mutation in BIRC3 (Baculoviral IAP repeat-containing protein 3) in this patient’s DLBCL
that are absent from his MZL, suggesting that these genetic alterations contributed to the large cell transformation.
Conclusions: To our knowledge, this is the first report providing molecular evidence for a previously suspected link
between MZL and DLBCL-IF. In addition, we describe for the first time del(20q12) and a missense mutation in BIRC3
in DLBCL. Our findings also raise awareness of DLBCL-IF and discuss the diagnostic pitfalls of this rare entity.
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Background
Diffuse large B-cell lymphoma (DLBCL), the most com-
mon type of non-Hodgkin lymphoma, is defined as a
neoplasm of large B lymphocytes that display a diffuse
growth pattern [1]. DLBCL is a quite diverse group of
malignancies with respect to cell morphology, pathogen-
esis, clinical presentation, and therapeutic response [1–
3]. Gene expression profiling studies identified two
major subgroups of nodal DLBCL based on the “cell of
origin”: the germinal center (GC) B-cell-like DLBCL (GCB
DLBCL) and the prognostically less favorable activated
B-cell-like DLBCL (ABC DLBCL) [4]. Immunohistochemi-
cal signatures were developed to translate the molecular
signatures and distinguish between the GCB DLBCL and
non-GCB DLBCL [5].
The World Health Organization (WHO) classification
distinguishes numerous subtypes of DLBCL [1]. In the
majority of the cases, DLBCL leads to effacement of the
nodal architecture by a diffuse infiltrate of malignant
cells. Rarely, however, DLCBL can show an interfollicu-
lar pattern (DLBCL-IF) of proliferation, preserving the
lymphoid follicles [6]. These cases constitute only about
1% of all DLBCL, frequently display a polymorphous ap-
pearance microscopically due to the admixture of non-
neoplastic inflammatory cells, and often present a diag-
nostic challenge. Previous reports indicate that DLBCL-
IF are predominantly of non-GCB type [6, 7]. Interest-
ingly, the interfollicular large B cells in normal lymph
node also show a non-GCB phenotype and share some
immunophenotypic characteristics with monocytoid B
cells [8]. It has been postulated that DLBCL-IF is derived
from marginal zone B cells and may represent a large-
cell transformation of an underlying MZL [7], however,
no direct evidence has been provided to date. The over-
all survival rate and prognosis of the DLBCL-IF seems
to be better than that of a non-IF DLBCL as control
group (DLBCL-CG) as the majority of cases present in
stage 1 or 2, show significantly lower International Prog-
nostic Index (IPI) scores than the DLBCL-CG [6]. Con-
sequently, it has been previously suggested that DLBCL-
IF is a distinct clinicopathologic entity [7].
In the case described here, we provide a direct evi-
dence genetically linking DLBCL-IF and MZL. Further-
more, we identify a novel del(20q12) and a BIRC3
missense mutation in DLBCL-IF, but not the patient’s
preceding MZL involving skin, strongly suggesting that
these genomic alterations are at least in part responsible
for the large cell transformation.
Materials and methods
Histology and immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were
stained with hematoxylin and eosin (H&E). Immunohis-
tochemical stains were performed on 4 μm tissue
sections using an Autostainer (Leica BOND platform,
Buffalo Grove, IL) according to manufacturer’s instruc-
tions. Sections were deparaffinized in xylene and graded
alcohols. Detection of the antibodies was performed
using a chromogenic substrate, diaminobenzene
(DAKO). The following antibodies were used: CD1a,
CD3, CD5, CD10, CD20, CD23, CD30, CD79a, BCL6,
Oct-2, BOB.1 (all from Leica), CD2, CD8, BCL2, CD45,
CD68, CD138, CD163, MUM-1/IRF4, ALK, Ki67, p53
(all from Dako), BCL1 (Fisher), c-MYC (Epitomics),
PAX5 and CD15 (both BD Bioscience), CD4 (Biocare),
CD56 (Zymed/Invitrogen), CD57 (Thermofisher), PD-1
(Abcam), TIA1 (Immunotech), and panCK (Biogenex),
Molecular analysis for clonality
DNA was extracted from either fresh tissue (i.e., skin) or
paraffin embedded (i.e., lymph node) tissue. PCR ampli-
fication was subsequently performed using two sets of
fluorescently-labeled primers (InVivoScribe Technolo-
gies) that hybridize to a conserved V-framework (i.e.,
FR2 or FR3) region and the conserved J-region of im-
munoglobulin heavy chain (IGH) gene. The PCR prod-
ucts were size separated by capillary electrophoresis on a
3500xL Genetic Analyzer (Life Technologies). Data were
analyzed (GeneMapper v5.0 software) and then reviewed
for peak patterns consistent with a clonal expansion.
Fluorescence in situ hybridization (FISH) analysis
FISH was performed on 3 μm formalin-fixed paraffin
embedded sections using the Vysis LSI D20S108 (20q12)
SpectrumOrange probe and the Vysis CEP 8 (D8Z2,
8p11.1-8q11.1 alpha satellite) SpectrumGreen (Abbott
Molecular Laboratories, Abbott Park, IL), according to
the manufacturers’ instructions. In brief, slides were
deparaffinized using xylene incubation (×3), followed by
ethanol wash steps (100, 70%). Prior to hybridization the
slides were treated with Dako Pre-Treatment solution
(Dako, Inc K5799) followed by digestion with pepsin
(37 °C, 15 min). Slides were dehydrated in ethanol (70,
85, 100%), dried and the FISH probes were added and
incubated overnight. The following morning the slides
were washed, counterstained with DAPI and manually
visualized and scored.
Gene mutation analysis
Detection of single nucleotide variants (SNVs) and inser-
tions/deletions (indels) analysis of paraffin-embedded
skin and lymph node tissue samples was performed by
the University of Pennsylvania clinical genomics labora-
tory, the Center for Personalized Diagnostics. The genes
sequenced were part of a custom, targeted next-
generation sequencing amplicon panel for 68
hematologic malignancy-associated genes (TruSeq Cus-
tom Amplicon, Illumina Inc.) based on previously
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described analyses [9, 10]. Briefly, individual library
preparations were pooled and concurrently sequenced
on the Illumina MiSeq (Illumina, Inc.). To assure a mini-
mum read depth of 250×, the mean depth of coverage
across the entire panel was 2000×. Detection of SNVs
was validated to a 4% allele frequency and large indels to
a 1% allele frequency. A separate assay was performed in
parallel to sequence the CEBPA gene using long range
PCR to isolate the gene and library preparation was per-
formed using the tagmentation-based Nextera library
preparation kit (Illumina, Inc.). The CEBPA gene was se-
quenced in tandem with the hematologic next-
generation sequencing panel and reported together with
the custom heme-NGS panel.
A custom bioinformatics pipeline was utilized to de-
tect alterations [11]. Manual review of the data in-
cluding visualization of variants was performed on all
samples following bioinformatics processing variants,
with variants compared with our knowledgebase and
on-line databases for further curation, using human
reference sequence UCSC build hg 19 (NCBI build
37.1) for comparison. Single nucleotide polymor-
phisms (SNPs) with a minor allele frequency (MAF) >
0.1% were considered benign and were not reported;
these calls were based on the Exome Variant Server
(http://evs.gs.washington.edu/EVS), the ExAC browser
(http://exac.broadinstitute.org) and dbSNP. Reported
variants used nomenclature based on the Human
Genome Variation Society nomenclature guidelines
(http://www.hgvs.org/mutnomen) and internally cate-
gorized into five different categories (benign, likely
benign, variant of uncertain significance, likely
pathogenic, pathogenic); the categories likely benign,
variant of uncertain significance and likely pathogenic
were reported as variants of uncertain significance in
the electronic health record.
Flow cytometry
Flow cytometry was performed on representative tissue
from the inguinal lymph node using the FACSCantoII
flow cytometer from BD Immunosystems. Samples were
prepared by aliquoting 50–75 μL of prepared cell sus-
pension into reagent tubes. Twenty microliter of rabbit
blocking reagent was added to the B cell clonality tube
and allowed to incubate at 37 °C for 20 min and 20 μL
of rabbit serum was added to the remainder of the tubes.
Laboratory prepared and premixed antibody cocktail
was added in 20 μL aliquots to each designated tube and
allowed to incubate in the dark for 20 to 30 min. The
cells were then washed with 3 to 5 ml of wash buffer
that was added to each tube, followed by centrifuging at
1450 rpm for 5 min at 10 °C. The cell pellet was resus-
pended in 0.5 ml of wash buffer and 10 μL of DAPI
working solution was added to each tube. Data is then
acquired on the flow cytometer.
Case presentation
Clinical findings
A 53-year-old man was evaluated in our Dermatology
Clinic due to a 1-year history of generalized itching, fa-
tigue of 2–3 month’s duration, nausea over the past
month, and a new left mid back rash. A physical exam
was essentially unremarkable except for a 1.2 cm red/
purple plaque on the left mid back that was biopsied.
Basic blood work was within normal limits. PET/CT was
performed and revealed inguinal, pelvic, retroperitoneal,
axillary, and cervical lymphadenopathy. The patient was
referred to surgery for excisional biopsy of a right in-
guinal lymph node. Of note, a CT scan performed 4 years
earlier had demonstrated inguinal lymphadenopathy
(3.8 cm lymph node). No additional workup was done at
that time. A follow-up CT scan performed 2 years later
showed mildly prominent bilateral axillary lymphaden-
opathy. One year prior to the current evaluation, the pa-
tient noted swelling in the right and left axilla.
Pathologic findings
Skin biopsy
The H&E-stained sections demonstrated a dense nodu-
lar lymphoid infiltrate in the superficial and deeper der-
mis without involvement of the epidermis (Fig. 1a). The
infiltrate was composed of predominantly small lympho-
cytes with scattered larger transformed cells with immu-
noblast morphology (Fig. 1b). Immunohistochemical
stains demonstrated nodules of CD20 positive B cells
around and within follicles, with scattered larger inter-
follicular B cells also present (Fig. 1c). CD3 stain
highlighted abundant interfollicular T lymphocytes (not
shown). Essentially all neoplastic B cells as well as many
of the interfollicular T cells were positive for BCL2
(Fig. 1d). BCL6 was negative in the tumor cells. The
findings were consistent with cutaneous involvement by
marginal zone lymphoma.
Excisional biopsy of the right inguinal lymph node
The H&E stained sections showed a lymph node with an
overall well-preserved nodal architecture including re-
active lymphoid follicles with well-demarcated mantle
zones (Fig. 2a). The interfollicular zones were, however,
expanded by numerous large atypical mononuclear cells
admixed with abundant eosinophils, small lymphocytes,
plasma cells and histiocytes (Fig. 2a and b). The larger
cells had oval to slightly irregular nuclear contours, ves-
icular chromatin, prominent nucleoli, and scant to mod-
erate amount of clear to amphophilic cytoplasm (Fig. 2c
and d). Immunohistochemical stains showed that the
large cells were positive for B-cell markers CD20
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(Fig. 2e), PAX5 (Fig. 2f ), and CD79a, as well as BCL6
(subset), CD30 (Fig. 2g), MUM1(Fig. 2h), CD23, c-MYC
(40–50%), p53 (dim in 40% of the large cells), BOB.1
(variable) and Oct-2 (variable). The Ki-67 proliferation
index in the interfollicular areas was high, exceeding
70%. Key negative stains included BCL2, CD10, and
CD15. CD138 highlighted plasma cells with a kappa
to lambda ratio of 3:1. An in-situ hybridization study
for Epstein-Barr virus (EBER) was negative. CD20,
PAX5 and CD79a stains also marked the abundant
reactive follicles with CD10+, BCL6+ and BCL2- ger-
minal centers and BCL2+ mantle zones. The prolifer-
ation index within the germinal centers was high as
expected (>90%) and highlighted the polarized light
and dark zones. The infiltrating small T lymphocytes
were positive for CD2, CD3, CD5 and CD7 (major
subset). The CD4 to CD8 ratio was increased (>5:1).
CD57 and PD-1 were positive in a subset of germinal
center T cells whereas TIA1, perforin, and granzyme
B were positive in scattered small interfollicular T
cells with a pattern similar to CD8 staining. CD56
and ALK-1 stains were negative. CD68, CD163, and
CD1a stained scattered histiocytes and accessory cells
respectively.
Ancillary studies on the lymph node specimen
Flow cytometry studies were performed on represen-
tative tissue from the right inguinal lymph node. As
shown in Fig. 3a–c, there was a large population of
CD19+ B lymphocytes (51% of all lymphoid cells)
with a strong lambda bias bordering on overt restric-
tion (kappa: lambda ratio of 0.33 and 0.27 for the
CD19+ and CD20+ cells, respectively). Minor subsets
of all B lymphocytes were CD5+ (Fig. 3a) or CD10+
(Fig. 3d); these cells expressed predominantly kappa
and, hence, were not part of the apparent lambda
clone.
Molecular studies for IGH gene rearrangement per-
formed on the skin biopsy showed a 281 base pair (bp)
peak in framework 2, as well as 94 bp and 115 bp peaks
in framework 3 (Fig. 4). Examination of tissue obtained
from the right inguinal lymph node demonstrated the
same 281 bp peak in framework 2 and the same 115 bp
peak in framework 3 whereas the 94 bp peak seen in the
skin specimen was not seen in the lymph node (Fig. 4b).
The overall results indicate that the lymphoproliferative
disorders involving lymph node and skin are clonally re-
lated. The significance of the 94 bp peak is unclear, but
it may represent a separate (sub-)clonal expansion. No
Fig 1 Histological findings of the skin biopsy from initial presentation. a Low magnification (25×) demonstrating a nodular infiltrate in the
superficial and deeper dermis (H&E). b At higher power (400×) the majority of the cells are small and have irregular nuclei and inconspicuous
nucleoli. There are scattered large transformed immunoblasts (H&E). c CD20 stain highlights the nodules of B lymphocytes (CD20
immunohistochemical stain, 50×) d The B lymphocytes in the nodules are positive for BCL2 (BCL2 immunohistochemical stain, 50×)
Hatem et al. Diagnostic Pathology  (2016) 11:137 Page 4 of 10
clonal T-cell receptor (TCR) rearrangement was de-
tected in the lymph node specimen.
FISH studies for rearrangements of MYC, BCL2, and
BCL6 performed on the lymph node were also negative.
Previous report described del(20q) in MZL with aggres-
sive features [12]. Since this patient’s DLBCL was
thought be derived from a MZL, additional FISH ana-
lysis for a 20q12 deletion was performed on both skin
and lymph node material to determine whether this
abnormality may be present. The analysis revealed that
38/150 (25.3%) of cells in the involved lymph node were
harboring del(20q12) (Fig. 5), whereas the skin lesion
was negative for this deletion (data not shown).
Targeted DNA sequencing studies using our
hematologic malignancy panel on the lymph node tissue
did not reveal any known disease-associated mutations,
however it did identify two variants of uncertain signifi-
cance (Table 1): a missense variant in BIRC3 (Baculoviral
Fig. 2 Histological findings of the inguinal lymph node excision 2 weeks after initial presentation. a Low-power view (25×) shows a lymph node with a
preserved architecture with intact capsule, patent sinuses and polarized germinal centers with well-demarcated mantle zones. The interfollicular areas are
expanded (H&E). b At higher magnification (100×) the interfollicular infiltrate is composed of numerous large transformed immunoblasts in the background
of small lymphocytes, abundant eosinophils, scattered plasma cells and histiocytes (H&E). c At 200× magnification (H&E) and (D) at 400× magnification the
large atypical cells have large oval to slightly irregular nuclei with vesicular chromatin, prominent nucleoli and scant to moderate amounts of clear to
amphophilic cytoplasm (H&E). e The large atypical cells are immunoreactive for CD20 (CD20 immunostain, 50×) as well as for f PAX5 (PAX5 immunostain,
200×), g CD30 (CD30 immunostain, 200×) and h MUM1 (MUM1 immunostain, 200×)
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IAP repeat-containing protein 3) at amino acid 572 con-
verting the wild type residue, cysteine, to tyrosine in
BIRC3 (p.C572Y→ c.1715G > A) in 491 reads out of a
total 9155 sequence reads for an allele frequency of
5.36% and a missense variant in EZH2 gene (Enhancer
of Zeste Homolog 2) at amino acid 322 converting the
wild type residue, Asparagine, to Serine (p.N322S→
c.965A > G) in 818 reads out of a total 1561 sequence
reads for an allele frequency of 52.40% . Subsequent se-
quencing studies of the skin revealed the same missense
variant in EZH2 as in the lymph node in 1097 reads out
of a total 2165 sequence reads for an allele frequency of
Fig. 3 Flow cytometric analysis of representative tissue from the inguinal lymph node. a The CD19/CD5 plot demonstrates and admixture of
CD19-positive B cells and CD5-positive T cells. b Gating on the CD19 positive B cells demonstrates a clear lambda bias. c the lambda bias of is
also seen when gating on CD20 positive B cells. d The majority of the CD19 positive B cells were found to be CD20 positive and CD10 negative.
The presence of a subset of CD10 positive B cells and subset positivity for kappa light chain staining is compatible with germinal center B cells
that are admixed with the malignant B cells
Fig. 4 IGH PCR analysis of both specimens revealed a shared pattern of peaks. a Primers for FR2 region identified a clonal peak at approximately
281 bp in the skin and the lymph node. b Similarly, a reproducible peak at approximately 115 bp was identified with primers targeting the FR3
region of IGH. An additional 94 bp peak was identified in a polyclonal background in the skin but not lymph node specimen
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50.67% but no other alterations, including the BIRC3
mutation, were identified.
Discussion
We report a rare case of a DLBCL with an interfollicular
pattern of involvement (DLBCL-IF) with sparing of the
nodal architecture including lymphoid follicles. This pat-
tern is common in peripheral T-cell lymphoma, not
otherwise specified (PTCL, NOS) that shows prolifera-
tion of malignant cells in the paracortex [1]. Our case
showed that the large malignant cells were admixed with
an inflammatory infiltrate including abundant eosino-
phils. It has been reported that approximately 60% of
DLBCL-IF cases contain reactive inflammatory cells that
are admixed with the large cells, a feature that is fre-
quently seen also in PTCL, NOS [1, 6, 7]. Thus, DLBCL-
IF can mimic histological picture of PTCL, NOS and it
is of utmost importance to be aware of this entity, as
PTCL-NOS carries a worse prognosis than DLBCL-IF
and calls for different therapeutic approaches. Therefore,
immunohistochemistry studies are required to differenti-
ate between these two entities. It is important to keep in
mind that both these types of lymphoma can be immu-
noreactive for CD30. Furthermore, it is critical to always
consider DLBCL-IF in the differential diagnosis of atyp-
ical interfollicular proliferations. Since distinguishing it
from a reactive interfollicular hyperplasia may be some-
times difficult, given the abundant background of in-
flammatory cells often seen in this type of lymphoma,
additional ancillary testing including IGH gene re-
arrangement studies and flow cytometry may prove par-
ticularly useful to establish the diagnosis.
It has been postulated that DLBCL-IF may be derived
from marginal zone B cells and may represent a large-
cell transformation of a MZL [7, 8]. To date, however,
there was no direct evidence to confirm this hypothesis.
Here we show for the first time a direct link between a
MZL and DLBCL-IF by demonstrating the presence of
the same clonal IGH rearrangement in the patient’s skin
and nodal biopsies. Furthermore we identified
del(20q12) in the DLBCL-IF. This genetic abnormality
has not been reported to date in a DLBCL of any kind.
Deletion of chromosome 20q is a common cytogenetic
abnormality in various myeloid neoplasms, most notably
myelodysplastic syndrome [1, 13, 14] but its association
with lymphoid malignancies is rare and limited to a few
reports. This includes a case of lymphoplasmacytic
lymphoma/Waldenström macroglobulinemia [15] and
two cases of marginal zone lymphoma [12, 16]. Another
study of 64 patients with chronic lymphocytic leukemia
(CLL) revealed that del(20q) appears to be a therapy-
related abnormality in CLL involving both myeloid and
lymphoid cells and may represent disease progression
[17, 18]. Given that del(20q12) in this patient was identi-
fied in the lymph node and not skin lesion and that the
patient has not received any prior chemotherapy at that
time, this abnormality is likely related to transformation
of MZL to DLBCL and implicates a loss of important
gene(s) likely with tumor suppressor function. Potential
candidate genes that map to this region include MYBL2
[19], Dido [20], L3MBTL1 [21] and SAMHD1 [22].
Next-generation sequencing studies using a custom
panel of 68 hematologic malignancy-associated genes re-
vealed the same missense variant in EZH2 in both the
skin and lymph node specimen and a missense variant
in BIRC3 that was present only in the lymph node speci-
men. The EZH2 variant was listed in all three databases
searched at very low allele frequencies (5 cases in
Fig. 5 FISH analysis of the lymph node specimen. Representative images of FISH analysis of the lymph node specimen using probes specific for
chromosome 20 (20q12, red) and centromere of chromosome 8 (green). a Cell positive for del(20q) and b cell negative for del(20q)
Table 1 Summary of identified missense variants in the lymph node and skin biopsy specimens
Gene alteration Protein change Nucleotide change Frequency in lymph node Frequency in skin
BIRC3 C572Y c.1715G > A 5.36% 0%
EZH2 N322S c.965A > G 52.40% 50.67%
Abbreviations: A adenine, C cysteine, c. coding, G guanine, N asparagine, p. protein, S serine, Y tyrosine
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COSMIC, in 4/13002 alleles in the exome variant server,
and 37/121,370 alleles in the ExAC database).
The missense variant in BIRC3 (p.C572Y→ c.1715G >
A), not reported in any of the three databases searched
(see methods section), was detected only in the lymph
node but not skin specimen at an allele frequency of
5.36%. Morphologic examination revealed that the
tumor comprises about 10-15% of the lymph node speci-
men. When these two observations are taken together,
the data imply that the BIRC3 mutation may be present
in a heterozygous state within the neoplasm (i.e., a
tumor burden of approximately 10% with a heterozygous
mutation would be expected to generate an allelic bur-
den of approximately 5%). So, even though this variant
has not been previously described, the circumstantial
evidence implies this is an oncogenic mutation that oc-
curred in the malignant DLBCL-IF cells.
The fact that this mutation was only seen in the
lymph node and not in the skin biopsy strongly sug-
gests that it may have contributed to transformation
of this patient’s MZL to DLBCL. BIRC mutations are
not among the recurrent mutations in the “standard”
DLBCL according to a recent report [23]. BIRC3 gene
located on chromosome 11 at 11q22.2 encodes cIAP2
(cellular inhibitor of apoptosis 2), that acts as an E3
ubiquitin ligase that regulates NF-kappa-B signaling
and affects a variety of cell functions including apop-
tosis, proliferation and immune modulation [24, 25].
Of note, proteins from the IAP family are potential
therapeutic targets in hematological malignancies [26].
BIRC3 mutations have been identified in various small
B cell lymphomas including chronic lymphocytic
leukemia (CLL) and splenic marginal zone lymphoma
(SMZL) [27, 28]. More recent studies demonstrate the
role of the ubiquitin ligases, both cIAP2 and a closely
structurally related cIAP1, encoded by the BIRC2
gene, in NF-κB signaling triggered by the B cell re-
ceptor (BCR) in DLBCL cells [29].
The alteration in EZH2 gene (p.N322S→ c.965A > G)
was observed with an allele frequency of approximately
50% in both specimens and this most likely represents a
benign/low-oncogeneic potential polymorphism rather
than a highly oncogenic mutation. EZH2 gene on 7q36
encodes the histone methyltransferase which initiates
epigenetic silencing of genes [30] and plays a role in nor-
mal B cell development [31]. EZH2 is mutated in a var-
iety of tumors including lymphomas and targeting of
EZH2 protein with specific inhibitors show promising
results in preclinical studies and early clinical trials [32–
34]. Interestingly, it has been reported that EZH2 poly-
morphisms may contribute to susceptibility of tumor de-
velopment and predict overall survival in some cancers
[35–38] and may have also contributed to progression of
the disease in this patient.
Conclusions
In summary, we present a rare case of diagnostically
challenging DLBCL with an interfollicular pattern and
provide data that support the hypothesis that DLBCL-IF
can arise from a MZL. To our knowledge, this repre-
sents the first reported case where DLBCL-IF and MZL
are shown to be clonally related. We identify a novel
del20q and a BIRC3 missense mutation in this patient’s
DLBCL-IF that have not been previously reported in
DLBCL. Given the absence of both these genetic abnor-
malities in the patient’s MZL, they both may have con-
tributed to the large cell transformation.
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